Edwards Lifesciences Corporation $EW Shares Sold by NewEdge Advisors LLC

Key Points

• NewEdge Advisors cut its Edwards Lifesciences stake by 77.3% in the first quarter, selling 20,977 shares and retaining 6,161 shares worth approximately $493,000. Institutional investors and hedge funds collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly EPS of $0.78, beating estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion. The company provided third-quarter 2026 EPS guidance of $0.71–$0.77 and full-year guidance of $2.95–$3.05.
• The stock opened at $89.89, while analysts maintain a “Moderate Buy” consensus with an average price target of $100.27; recent targets range from $95 to $110.

NewEdge Advisors LLC decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 77.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,161 shares of the medical research company's stock after selling 20,977 shares during the period. NewEdge Advisors LLC's holdings in Edwards Lifesciences were worth $493,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group increased its position in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock valued at $546,000 after purchasing an additional 130 shares during the period. McIlrath & Eck LLC lifted its holdings in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company's stock valued at $90,000 after buying an additional 135 shares during the period. Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences by 0.9% during the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock valued at $1,288,000 after buying an additional 136 shares in the last quarter. Stephens Inc. AR boosted its stake in Edwards Lifesciences by 5.4% during the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock valued at $239,000 after buying an additional 144 shares in the last quarter. Finally, Composition Wealth LLC grew its holdings in Edwards Lifesciences by 1.6% during the fourth quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company's stock worth $795,000 after acquiring an additional 147 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.1%

Shares of NYSE EW opened at $89.89 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a market cap of $51.76 billion, a price-to-earnings ratio of 51.66, a P/E/G ratio of 2.26 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $89.21 and a 200-day simple moving average of $84.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences's revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EW shares. Truist Financial boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. UBS Group initiated coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price objective for the company. Evercore reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Barclays reiterated an "overweight" rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source